⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ACRV News
Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
globenewswire.com
ACRV
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
globenewswire.com
ACRV
Form 8-K
sec.gov
ACRV
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
globenewswire.com
ACRV
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
globenewswire.com
ACRV
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
globenewswire.com
ACRV
Form 8-K
sec.gov
ACRV
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
globenewswire.com
ACRV
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ACRV
Form 8-K
sec.gov
ACRV